TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03334617
Drug: AZD6738 (ceralasertib) 7 days monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
Study: NCT03762018
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
Study: NCT00334386
Drug: Torasemide Prolonged Release (loop diuretic)
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00334386
Drug: Torasemide Immediate Release (loop diuretic)
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01439542
Drug: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Normalized name: Luteinizing hormone
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 months (2x6 month depot) of androgen suppression with LHRH agonist
Study: NCT00770770
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 µg/day
Study: NCT00770770
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 µg/day
Study: NCT03762018
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
Study: NCT03762018
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
Study: NCT00005576
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00138060
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m² or 260 mg/m² in 90 minutes every 15 days
Study: NCT04439396
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nonsteroidal anti-inflammatory drug
Study: NCT02285738
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81mg/day for 4 weeks
Study: NCT01650428
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
Study: NCT01650428
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
Study: NCT01650428
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
Study: NCT02231008
Drug: tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01496742
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg iv, Day 1 of each 21-day cycle
Study: NCT01496742
Drug: cisplatin/carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles
Study: NCT01496742
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
Study: NCT01888081
Drug: A-dmDT390-bisFv(UCHT1) (Resimmune®)
Normalized name: Padimate A
DrugBank: A-dmDT390-bisFv(UCHT1) (DB16307)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04448223
Drug: CKD-351
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
Study: NCT04448223
Drug: Latanoprost+Dorzolmamide
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
Study: NCT01496742
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2, Day 1 of each 21-day cycle
Study: NCT03762018
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
Study: NCT02780687
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00254423
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03840512
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.
Study: NCT01062256
Drug: Guaifenesin
Normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 400 mg immediate release tablet administered orally as a single dose
Study: NCT00112775
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00112775
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00137397
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02137265
Drug: Clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg orally daily
Study: NCT02620280
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
Study: NCT03523858
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
Study: NCT03448393
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
Study: NCT02620280
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
Study: NCT00572026
Drug: Methylphenidate Transdermal System
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daytrana wear time up to 15 hours
Study: NCT00193869
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00923156
Drug: aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
Study: NCT00923156
Drug: ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg , 5.0 mg or 10 mg once daily
Study: NCT00923156
Drug: Placebo to aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: matching placebo to aliskiren in double blind phase
Study: NCT00923156
Drug: Placebo to ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo to ramipril capsule in double blind phase
Study: NCT00609193
Drug: lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard clinical care
Study: NCT00609193
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard clinical care
Study: NCT02427451
Drug: Bcl-2 Inhibitor GDC-0199
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02427451
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04534491
Drug: Oxybutynin (Oxytrol, BAY839380)
Normalized name: oxyBUTYnin Transdermal System [Oxytrol]
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
Study: NCT03000179
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab through a vein once every 2 weeks
Study: NCT00053950
Drug: pyrazoloacridine
Normalized name: Pyrazoloacridine
DrugBank: Pyrazoloacridine (DB12549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00890149
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (4ug/kg bid),
Study: NCT01010698
Drug: cimetidine (or acyclovir)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cimetidine (or acyclovir) 200mg (single dose)
Study: NCT04086121
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for SC injection
Study: NCT02624557
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single dose of 300 mg alpelisib.
Study: NCT01908725
Drug: Lamazym
Normalized name: Lamazym
DrugBank: Velmanase alfa (DB12374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT, i.v. infusions weekly
Study: NCT02353169
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02353169
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00991718
Drug: GDC-0449 oral capsules (non-labeled)
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg oral capsule
Study: NCT03193333
Drug: Timolol eye drops
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop every 12 hours for 90 days
Study: NCT03193333
Drug: Dorzolamide-Timolol Ophthalmic
Normalized name: dorzolamide-timolol ophthalmic
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop every 12 hours for 90 days
Study: NCT03193333
Drug: Brimonidine Ophthalmic Solution
Normalized name: brimonidine Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop every 12 hours for 90 days
Study: NCT02299999
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target: MEK
Study: NCT02299999
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target: VEGF, EGFR
Study: NCT02299999
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target: Androgen receptor
Study: NCT02299999
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Target: PARP
Study: NCT00991718
Drug: GDC-0449 IV injection (labeled)
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mcg (in 2 mL) IV dose of 14C-GDC-0449
Study: NCT00991718
Drug: CDC-0449 oral suspension (labeled)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
Study: NCT02299999
Drug: Platinum based chemotherapies
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum based chemotherapies
Study: NCT02299999
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Target: VEGF
Study: NCT02299999
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkylating agents
Study: NCT02299999
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microtubule modulator
Study: NCT01823965
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00440557
Drug: Epoetin alfa once weekly
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
Study: NCT00440557
Drug: Epoetin alfa once every two weeks
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
Study: NCT01572948
Drug: roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
Study: NCT00365508
Drug: nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotine lozenge
Study: NCT00365508
Drug: nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal nicotine patch
Study: NCT02921737
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
Study: NCT02555111
Drug: Xarelto
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/day oral administration during 2 to 4 years (based on the recruitment date).
Study: NCT00699465
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
Study: NCT00699465
Drug: enoxaparin placebo
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
Study: NCT00038727
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as 850mg twice per day, masked in DPP and open label in DPPOS
Study: NCT00436553
Drug: Verteporfin Photodynamic Therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
Study: NCT00436553
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5 mg administered as an intravitreal injection.
Study: NCT00436553
Drug: Verteporfin Placebo
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Study: NCT00436553
Drug: Ranibizumab Placebo
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
Study: NCT00192569
Drug: Pegylated Interferon alfa 2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
Study: NCT00192569
Drug: Ribavirin (HIV conifected patients only)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
Study: NCT01190345
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
Study: NCT01190345
Drug: no bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: no bevacizumab
Study: NCT01941966
Drug: Mitomycins
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
Study: NCT03820466
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application of platelet inhibiting medication
Study: NCT03820466
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application of lipid lowering medication
Study: NCT03820466
Drug: Placebo Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application of placebo
Study: NCT00716248
Drug: bucillamine
Normalized name: bucillamine
DrugBank: Bucillamine (DB12160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bucillamine 100 mg, twice a day
Study: NCT02504359
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given BEAM chemotherapy
Study: NCT02504359
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given BEAM chemotherapy
Study: NCT02504359
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given BEAM chemotherapy
Study: NCT02504359
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02504359
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given BEAM chemotherapy
Study: NCT01275586
Drug: Tasigna
Normalized name: Tasigna
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
Study: NCT03793023
Drug: Teneligliptin 20mg
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT02504359
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT01703039
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01703039
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03926754
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).
Study: NCT00814671
Drug: Rifapentine 450
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifapentine 450 mg
Study: NCT00814671
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifapentine 600 mg
Study: NCT00814671
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampin 600 mg
Study: NCT03855332
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See above